Biosimilar Development News

  1. Biosimilars Market: 5 Companies You Know And Five Companies You Need To Know
    11/21/2017

    Some of the world's largest biopharmaceutical products, among the highest revenue generators in the pharmaceutical industry, may face competition from so-called "biosimilars," according to a new report from healthcare market research firm Kalorama Information.

  2. Clinical Leader Forum Names Boston and Philadelphia As 2018 Locations
    11/20/2017

    Philadelphia Agenda Announcement and Advisory Board Introduction

    November 20, 2017, Erie, PA: Life Science Leader and ClinicalLeader.com are excited to announce that Clinical Leader Forum will take place in Boston and Philadelphia in 2018. The Boston event is scheduled for October 3 – 4, 2018 at the State Room Boston. The Philadelphia event is scheduled for May 9-10, 2018 at the Hilton Philadelphia City Avenue.

  3. Samsung Bioepis Receives Regulatory Approval For Europe's First Trastuzumab Biosimilar, ONTRUZANT
    11/19/2017

    Samsung Bioepis Co., Ltd. recently announced the European Commission’s (EC) marketing authorization of ONTRUZANT, a biosimilar referencing Herceptin (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.

  4. Competitor Analysis: Anti-VEGF And Anti-VEGF-R Biosimilars And Biosuperiors Of Avastin, Cyramza, Eylea And Lucentis - A 2017 Update - Research And Markets
    11/17/2017

    The "Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - a 2017 Update" report has been added to Research and Markets' offering. 

  5. CMS Proposes Policies To Lower The Cost Of Prescription Drugs And Combat The Opioid Crisis
    11/17/2017

    Today, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that includes a number of changes that, if finalized, will ensure that Part D Medicare enrollees have access to more affordable prescription drugs and more robust prescription drug coverage at the pharmacy they prefer.

  6. British Columbia And Prince Edward Island Become The First Provinces To Add Erelzi (Etanercept) To Public Drug Plans For The Treatment Of Multiple Inflammatory Diseases
    11/17/2017

    British Columbia and Prince Edward Island are the first provinces to add Erelzi (etanercept) to their public drug plans for the treatment of multiple inflammatory diseases, respectively on November 14 and November 27.

  7. Anti-VEGF And Anti-VEGF-R Biosimilars And Biosuperiors Of Avastin, Cyramza, Eylea And Lucentis - 2017; New Report Launched
    11/16/2017

    The Competitive Intelligence Report "Anti-VEGF & Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update" provides a competitor evaluation in the field of recombinant antibodies, proteins and vaccines targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of November 2017.

  8. The Global Biosimilars Market Is Expected To Reach USD 13.1 Billion By 2024
    11/16/2017
  9. Theradiag And Biogen Sign A Partnership Agreement
    11/15/2017

    THERADIAG (ISIN code: FR0004197747, Ticker: ALTER) a company specialized in in vitro diagnostics and theranostics, is recently announcing that it has entered into a partnership agreement with Biogen to provide its LISA TRACKER kits for monitoring Flixabi (an infliximab biosimilar).

  10. New Data Reinforces Clinical Basis For Switching To Sandoz Biosimilar Medicines
    11/14/2017

    Sandoz, a Novartis division and the global leader in biosimilars, today announces data from four clinical studies comparing its proposed biosimilar adalimumab and biosimilar rituximab with their reference medicines, Humira and MabThera/Rituxan respectively.